Buy & Sell Moody's Corporation (MCO) – Moody's Corporation Price Today
Aura AI Summary
Key Stats
- $77.45BMarket Cap
- FinancialsSector
- -11.39%3M Drawdown
- $83.26BEnterprise Value
- 0.93%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 118 daysTypical Hold Time
Moody's Corporation (MCO) is currently valued at a market capitalization of $77.45B, with an enterprise value of $83.26B. Over the past 52 weeks, Moody's Corporation has traded between a low of $412.23 and a high of $539.61, highlighting its annual price range. Over the past three months, Moody's Corporation has recorded a drawdown of -11.39%, reflecting recent price volatility. Moody's Corporation offers a dividend yield of 0.93%, with the most recent dividend of $1.03 paid on 15 May 26. On average, investors hold Moody's Corporation for approximately 118 days, indicating typical investor behavior on the platform.
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Most Recent News
Vuzix showcases advanced waveguide smart glasses for defense at SOF Week 2026 in Florida
Vuzix Corporation is exhibiting its advanced AI-powered smart glasses and waveguide solutions at SOF Week 2026 in Tampa, Florida. These products are designed for defense use, offering mission-ready optical performance in challenging environments, inc...
Over 50 companies advance 55+ new pulmonary arterial hypertension drugs in clinical trials.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
ANKTIVA combo shows higher response rates and fewer side effects vs rival bladder cancer therapies
ImmunityBio presented data showing its ANKTIVA plus BCG treatment outperformed two FDA-approved bladder cancer therapies, Adstiladrin and INLEXZO. The ANKTIVA combo achieved a 69.7% complete response rate versus 53.4% for Adstiladrin, with a longer m...